Indeed, intratumoral administration of anti-CCL22 antibody inhibited B16F10 melanoma growth by decreasing Treg recruitment at the tumor site (21), suggesting that a reduction in tumor-derived CCL22 could suppress melanoma growth. This evidence concerns the gene CCL22 and melanoma.